Jangik Lee

Professor

Seoul National University

South Korea

Research Interests

Explore related searches

Professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jangik Lee is a Professor at Seoul National University in South Korea. His research focuses on pharmacokinetics, cancer treatment, and personalized medicine, as evidenced by his recent articles on nanoparticle albumin‐bound paclitaxel-induced peripheral neuropathy and dosage individualization for chronic myeloid leukemia. He is also involved in studies related to tuberculosis treatment and novel drug formulations for advanced solid tumors.

Articles (7)

Year:

2024

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Ji Kon Ryu

Seoul National University Hospital

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jangik Lee

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Factors affecting peripheral neuropathy induced by nanoparticle albumin‐bound paclitaxel in patients with pancreatic cancer

Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia

Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis

Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study

Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia

Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis

Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors

Collaborators (1)

Ji Kon Ryu

Make your next move.